| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Network-1 Technologies, Inc. (NYSE:NTIP), a company engaged in the acquisition, development, licensing, and monetization of intellectual property, announced today that ILiAD Biotechnologies, LLC reported the first-ever demonstration of protection against B. pertussis (whooping cough) colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine.
ILiAD announced that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study. To date, Network‑1 has invested an aggregate of $7,000,000 in ILiAD which represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.
Additional information regarding the Phase 2B Human Challenge study is contained in the press release issued by IliAD, which is available at https://www.iliadbio.com/company/news.html
Posted In: NTIP
